Answers are grounded in this paper and cite their sources.
Ten Eleven Translocation (TET) proteins are a family of dioxygenases (TET1, TET2, and TET3) that catalyze the oxidation of 5-methyl-cytosine (5mC) to 5-hydroxymehylcytosine (5hmC), 5-formlycytosine (5fC), and 5-carboxylcytosine (5caC) 1 . Mutations involving TET2 (4q24) have widely been reported in the context of age-related clonal hematopoiesis (~10% >80 years of age) 2 , and hematological malignancies such as myelodysplastic syndromes (MDS 5–20%), myeloproliferative neoplasms (MPN~15%), chronic myelomonocytic leukemia (CMML ~60%), acute myeloid leukemia (AML 8–30%), and T and B cell lymphoproliferative disorders 3 , 4 , 5 . In CMML, thus far, clonal TET2 mutations in the absence of clonal ASXL1 mutations ( ASXL1 wt/ TET2 mt) have been associated with favorable outcomes 6 . Conversely, mutations in TET1 (10q21.3) and TET3 (2p13.1) are extremely infrequent with a large study of 408 MPN, CMML, and AML patients demonstrating no identifiable mutations in these genes 3 . In a recent study, whole exome sequencing was performed in 49 CMML patients resulting in the detection of two loss-of-function, subclonal, TET3 mutations (R148H and S1708fs), both in patients with co-existing TET2 mutations 7 . ASXL2 (additional sex combs-like; 2p23.3) mutations were recently described in adult and pediatric patients with t(8;21)/core binding factor AML ( RUNX1–RUNX1T1 ) (~20%) and were associated with a higher cumulative incidence of relapse 8 . In MDS/MPN overlap syndromes including CMML, thus far, the frequency and prognostic impact of ASXL2 mutations remain unknown. We carried out this study to estimate the frequency and clinical correlates of TET1, TET3 , and ASXL2 mutations in patients with MDS/MPN overlap syndromes.
No takes yet. Share an insight, caveat, or question.
Lasho et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: